Founded in 2017, 48Hour Discovery (48HD) is a Canadian biotechnology company headquartered in Edmonton, AB with sites in San Diego, California and Seoul, South Korea. The 48HD genetically-encoded platform technology drives rapid discovery of leads in peptide & macrocycle therapeutics. 48HD will be opening a new round of investment in Q4 this year to accelerate internal drug programs.
To learn more please view our investors page
48HD uses genetically encoded phage displayed peptide and peptide derived libraries to discover target ligands. With over one billion medium sized peptides (200-3000 Dalton), the library ensures a “sweet spot” in protein-ligand recognition, unlike small molecule and antibody-based therapeutics. Four in-house encoded, proprietary libraries are currently available for screening services. The quality and diversity of each is guaranteed.
Single-round screening is applied when protein targets have defined binding sites e.g. antibodies. The outcome of such screening are linear epitope mapping or immunoprofiling. We recommend clients use our in-house linear or cyclic libraries
Multi-round screening is used to probe protein-protein interactions, or when targets are more complex, e.g. with shallow binding sites, or targets that form complex. In this case, we recommend clients using our cyclic, bicyclic, or GE-FBD/customized libraries.
We operate a proprietary cloud database service to store all results. This service enables access to results from anywhere in the world, with any device. In addition, search data that some academic partners have made public is available.
11421 Saskatchewan drive,
Office Telephone : 1-888-550-8579 ext: 101
mail : firstname.lastname@example.org
Inquiries : email@example.com